Silverarc Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Silverarc Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.13M	Sell	158,964 -137,171	-46%	-$2.04M	0.25%	57
2026 Q2	$4.85M	Sell	296,135 -5,594	-2%	-$73.3K	0.5%	52
2026 Q1	$3.94M	Sell	301,729 -5,811	-2%	-$77.9K	0.4%	48
2025 Q4	$3.52M	Buy	307,540 +141,379	+85%	+$1.61M	0.49%	47
2025 Q3	$1.95M	Buy	+166,161	New	+$1.34M	0.26%	63

Other funds holding CTNM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Silverarc Capital Management's CTNM Position: Q3 2026 in Review

Silverarc Capital Management reduced its Contineum Therapeutics (CTNM) stake by 46% in Q3 2026, selling an estimated $2.04M and leaving 158,964 shares worth $2.13M. The position accounts for 0.25% of the portfolio, ranked #57.

Silverarc Capital Management first reported a position in CTNM in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.85M in Q2 2026. 47 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

Silverarc Capital Management held 158,964 shares of Contineum Therapeutics worth $2.13M as of Q3 2026.
Silverarc Capital Management sold 137,171 Contineum Therapeutics shares in Q3 2026, an estimated $2.04M.
Contineum Therapeutics made up 0.25% of Silverarc Capital Management's portfolio in Q3 2026, its #57 holding.
Silverarc Capital Management first reported a position in Contineum Therapeutics in Q3 2025 and has held it in 5 quarters since.
Silverarc Capital Management's Contineum Therapeutics position peaked at $4.85M in Q2 2026.
47 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Silverarc Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.